CMPI Checkmate Pharmaceuticals, Inc. Stock Quote

CMPI [NASD]

Index	-	P/E	-	EPS (ttm)	-1.99	Insider Own	3.60%	Shs Outstand	21.56M	Perf Week	-8.88%
Market Cap	226.62M	Forward P/E	-	EPS next Y	-2.91	Insider Trans	3.50%	Shs Float	20.58M	Perf Month	-27.95%
Income	-42.90M	PEG	-	EPS next Q	-0.67	Inst Own	86.10%	Short Float	0.42%	Perf Quarter	-30.46%
Sales	-	P/S	-	EPS this Y	-21.70%	Inst Trans	-0.02%	Short Ratio	1.96	Perf Half Y	-14.13%
Book/sh	5.81	P/B	1.82	EPS next Y	11.00%	ROA	-46.90%	Target Price	-	Perf Year	-
Cash/sh	4.43	P/C	2.39	EPS next 5Y	45.10%	ROE	-481.10%	52W Range	8.61 - 23.10	Perf YTD	-27.55%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-62.51%	Beta	-
Dividend %	-	Quick Ratio	13.00	Sales past 5Y	-	Gross Margin	-	52W Low	0.58%	ATR	1.09
Employees	25	Current Ratio	13.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	25.67	Volatility	8.45% 8.59%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-12.90%	Profit Margin	-	Rel Volume	1.64	Prev Close	10.57
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	44.04K	Price	8.66
Recom	1.70	SMA20	-31.76%	SMA50	-36.81%	SMA200	-34.57%	Volume	55,693	Change	-18.07%

Apr-12-21 08:36AM	Checkmate Pharmaceuticals Releases Clinical Data For Vidutolimod And Pembrolizumab Combo SmarterAnalyst -18.07%
Apr-11-21 04:01PM	Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting GlobeNewswire
Apr-09-21 02:16PM	7 Beaten Down Stocks with Significant Insider Buying InvestorPlace
Mar-29-21 04:30PM	Checkmate Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Recent Progress GlobeNewswire -11.92%
Mar-10-21 04:30PM	Checkmate Pharmaceuticals to Present Data at the 2021 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Jan-04-21 04:30PM	Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team GlobeNewswire
Dec-20-20 02:14AM	Insider Buying: The Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Founder Just Bought US$71k Worth Of Shares Simply Wall St.
Dec-08-20 07:00AM	Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab GlobeNewswire +13.09%
Dec-01-20 06:30PM	Is Checkmate Pharmaceuticals (CMPI) A Good Stock To Buy Now? Insider Monkey
Nov-13-20 07:00AM	Checkmate Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides an Update on Recent Progress GlobeNewswire
Nov-09-20 09:00AM	Checkmate Pharmaceuticals Presents Updated Clinical Data with CMP-001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting GlobeNewswire +16.31%
Nov-07-20 08:58AM	We Think Checkmate Pharmaceuticals (NASDAQ:CMPI) Can Afford To Drive Business Growth Simply Wall St.
Nov-03-20 07:00AM	Checkmate Pharmaceuticals to Present at the Upcoming Jefferies Virtual London Healthcare Conference GlobeNewswire +6.17%
Oct-15-20 09:20AM	Checkmate Pharmaceuticals Announces Data Presentations for CMP-001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting GlobeNewswire
Sep-23-20 07:00AM	Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire
Sep-18-20 07:00AM	Checkmate Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides an Update on Recent Progress GlobeNewswire -6.81%
Sep-09-20 01:00AM	Kuros Biosciencess licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ GlobeNewswire +7.47%
Aug-06-20 09:17PM	Checkmate Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naive neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krieg Arthur M	Chief Scientific Officer	Mar 26	Buy	12.15	3,484	42,331	746,711	Mar 29 04:20 PM
Krieg Arthur M	Chief Scientific Officer	Mar 25	Buy	12.35	10,036	123,945	743,227	Mar 29 04:20 PM
Chaudhary Kleem	Chief Business Officer	Feb 26	Option Exercise	2.62	2,000	5,240	8,000	Mar 01 04:15 PM
Krieg Arthur M	Chief Scientific Officer	Jan 27	Buy	13.05	1,701	22,198	733,191	Jan 28 04:05 PM
Krieg Arthur M	Chief Scientific Officer	Jan 19	Buy	13.09	500	6,545	731,490	Jan 21 05:17 PM
Chaudhary Kleem	Chief Business Officer	Jan 14	Option Exercise	2.62	2,000	5,240	6,000	Jan 15 04:30 PM
Krieg Arthur M	Chief Scientific Officer	Dec 29	Buy	14.16	443	6,273	730,990	Dec 31 04:20 PM
Chaudhary Kleem	Chief Business Officer	Dec 22	Option Exercise	2.62	4,000	10,480	4,000	Dec 23 04:15 PM
Krieg Arthur M	Chief Scientific Officer	Dec 22	Buy	14.64	5,103	74,708	730,547	Dec 23 04:13 PM
Krieg Arthur M	Chief Scientific Officer	Dec 16	Buy	14.62	4,805	70,249	725,444	Dec 17 05:21 PM
Krieg Arthur M	Chief Scientific Officer	Dec 15	Buy	14.49	42	609	720,639	Dec 17 05:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience